Vitamin D Muscle Strength Randomized Trial: What the Evidence Says

Quick Answer

Vitamin D Muscle Strength Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Sarcopenia required confirmation of low muscle mass and/or impaired muscle strength or reduced physical performance according to established consensus-based diagnostic criteria, including the European Working Group on sarcopenia in Older People (EWGSOP2), the Asian Working Group for sarcopenia (AWGS), or the Foundation for the National Institutes of Health (FNIH) criteria. [Russo Cristina (2026); evidence level 1]
• Thus, vitamin D and resveratrol have been reported to modulate several regulatory pathways that govern inflammation, mitochondrial integrity, and muscle protein turnover, including NF-κB, PGC-1α, FOXO, and networks associated with AMPK and SIRT1 activity. [Russo Cristina (2026); evidence level 1]
• These disorders contribute to a further decline in skeletal muscle mass and function, significantly elevating the risk of sarcopenia. [Wang Lailiang (2026); evidence level 2]
• • Patients with ESRD complicated by sarcopenia may face a higher risk of adverse clinical outcomes. [Wang Lailiang (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For vitamin d muscle strength randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Russo Cristina (2026). Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials. DOI: 10.3389/fnut.2026.1818450. PMCID: PMC13216041. PMID: 42221760. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13216041/
• Wang Lailiang (2026). Effect of active vitamin D supplementation on muscle mass and function in peritoneal dialysis patients with sarcopenia: a randomized controlled trial. DOI: 10.1038/s41598-026-47141-1. PMCID: PMC13195084. PMID: 41933167. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13195084/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.